{"schema_version":"secwatch.filing_event.v1","accession":"0001701541-22-000017","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2022-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.894987+00:00","generated_at":"2026-06-25T21:06:00.618114+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Black Diamond Therapeutics Q1 net loss $25.5M; cash runway into Q3 2024; BDTX-1535 phase 1 dosed","bullets":["Net loss $25.5M vs $30.3M Q1 2021; R&D expense $17.8M (down from $22.8M).","Cash, equivalents, investments $179.7M; net cash used in ops $28.6M for Q1.","First patient dosed April 2022 in Phase 1 for BDTX-1535 (EGFR inhibitor, GBM/NSCLC); clinical update in 2023.","BDTX-4933 IND submission expected H1 2023; FGFR program candidate nomination in 2022.","Reduced workforce ~30% in April 2022; cash runway extended into Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001701541-22-000017","json":"https://secwatch.observer/filing/0001701541-22-000017.json","markdown":"https://secwatch.observer/filing/0001701541-22-000017.md","text":"https://secwatch.observer/filing/0001701541-22-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000170154122000017/0001701541-22-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000170154122000017/bdtx-20220511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:06:00.618114+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}